Table 2.
ACE2-binding inhibition against various SARS-CoV-2 variants by different doses of heterologous or homologous regiment and COVID-19 infection status.
| Infected | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Type- Number of doses | Homo-2 | Hetero-2 | P-value | Homo-3 | Hetero-3 | P-value | Homo-4 | Hetero-4 | P-value |
| MI % | MI % | MI % | MI % | MI % | MI % | ||||
| Wild type | 97.58% | 97.53% | 0.12 | 97.49% | 97.57% | 0.04 | 97. 25% | 97.63% | 0.81 |
| Omicron Variant B.1.1.529 | 66.75% | 75.09% | 0.03 | 62.45% | 80.17% | 0.03 | 67.81% | 88.91% | 0.38 |
| Omicron BA.2 Variant | 76.04% | 83.82% | 0.42 | 82.04% | 90.84% | 0.15 | 88.93% | 92.86% | 0.20 |
| Non-Infected | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Type- Number of doses | Homo-2 | Hetero-2 | P-value | Homo-3 | Hetero-3 | P-value | Homo-4 | Hetero-4 | P-value |
| MI % | MI % | MI % | MI % | MI % | MI % | ||||
| Wild type | 97.13% | 97.58% | 0.41 | 97.57% | 97.62% | 0.55 | 97.54% | 97.64% | 0.3 |
| Omicron Variant B.1.1.529 | 69.28% | 78.65% | 0.35 | 74.88% | 87.50% | 0.785 | 86.56% | 90.93% | 0.47 |
| Omicron BA.2 Variant | 85.61% | 86.32% | 0.90 | 83.09% | 94.15% | 0.0001 | 84.30% | 96.24% | <0.0001 |
*MI %, Percentage of Mean Inhibition.